Supplemental Table 2: Demographic, clinicopathologic, and treatment characteristics, and
postoperative morbidity and mortality in overall study cohort
All patients n = 343
Clinical characteristics
Age, mean (SD) 64.6 (10)
Sex, N (%) Female Male
85 (25) 258 (75)
Body weight, kg, mean (SD) 79 (15)
BMI, kg m-2, mean (SD) 27.4 (4)
Obesity, N (%) 79 (23)
Overweight, N (%) 223 (65)
Current smoker, N (%) 70 (20)
Metabolic syndrome, N (%) 134 (39)
Diabetes, N (%) 39 (11)
Hypertension, N (%) 129 (38)
Dyslipidemia, N (%) 60 (17)
Preoperative respiratory disease, N (%) 68 (20)
Treatment characteristics Treatment pathway, N (%) Neoadjuvant therapy Surgery first
232 (68) 111 (32)
§ Neoadjuvant regimen, N (%) Chemotherapy
Chemoradiation
90 (39) 142 (61) Operation type, N (%)
2-stage esophagectomy 3-stage esophagectomy Transhiatal esophagectomy Extended total gastrectomy
133 (39) 58 (17) 95 (28) 57 (17)
Thoracotomy, N (%) 206 (60)
Pathologic characteristics Histologic type, N (%) Adenocarcinoma Squamous cell carcinoma Other
260 (76) 79 (23)
4 (1) Clinical stage, N (%)
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
18 (5) 58 (17) 139 (41) 123 (36) 1 (0.3)
Clinical N stage positive, N (%) 135 (40)
Pathologic stage, N (%) (y)pT0
(y)pT1 (y)pT2 (y)pT3 (y)pT4
(y)pN0 (y)pN1 (y)pN2 (y)pN3
42 (12) 99 (29) 46 (13) 128 (38)
20 (6)
204 (60) 69 (20) 41 (12) 25 (7)
Postoperative morbidity
Clavien-Dindo Classification, N (%)
No complication 112 (33)